SLS009 Plus Venetoclax/Azacitidine Produces Responses in R/R AML, Including ASXL1+ Disease
SLS009 plus venetoclax and azacitidine elicited responses in patients with relapsed/refractory AML, particularly in those harboring ASXL1 mutations.
SLS009 plus venetoclax and azacitidine elicited responses in patients with relapsed/refractory AML, particularly in those harboring ASXL1 mutations.
Anne Chiang, MD, PhD, discusses understanding the heterogeneity of SCLC to determine which patients will respond to targeted therapy.
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Jean L. Koff, MD, MS, discusses key considerations in the choice of BTK inhibitors for frontline and maintenance treatment in MCL.
Apple cider vinegar, a liquid made from fermenting apples, is said to have many potential health benefits. But what does research say about these claims?…
Axel Hauschild, MD, elucidates the varying role of treatment for both cutaneous cell carcinoma and basal cell carcinoma that are seen globally.
An abstract is unavailable.
Melanoma risks and prevention in people of color: Understand the critical role of awareness, early detection, and the necessity of skin checks.
TNO155 combined with either spartalizumab or ribociclib showed acceptable safety and tolerability across solid tumors in a phase 1b open-label study.
Prolonged administration of imatinib maintenance therapy for 6 years improved disease-free survival in patients with gastrointestinal stromal tumors.
During Patient Experience Week, Moffitt proudly celebrated the exceptional efforts of its clinics with the Patient Experience Champions Awards.